104 related articles for article (PubMed ID: 22515602)
1. Breast cancer pharmacogenomics: where we are going.
Newman WG; Flockhart D
Pharmacogenomics; 2012 Apr; 13(6):629-31. PubMed ID: 22515602
[No Abstract] [Full Text] [Related]
2. Pharmacokinetics and pharmacogenomics in breast cancer chemotherapy.
Marsh S; Liu G
Adv Drug Deliv Rev; 2009 May; 61(5):381-7. PubMed ID: 19100797
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics of chemotherapy efficacy in breast cancer.
González-Neira A
Pharmacogenomics; 2012 Apr; 13(6):677-90. PubMed ID: 22515610
[TBL] [Abstract][Full Text] [Related]
4. Genetics, Genomics, and Pharmacogenomics.
Hughes KS; Cusack JC
Ann Surg Oncol; 2015 Oct; 22(11):3414-7. PubMed ID: 26215191
[No Abstract] [Full Text] [Related]
5. An interview with Pharmacogenomics for the breast cancer special focus issue.
Weinshilboum RM
Pharmacogenomics; 2012 Apr; 13(6):655-8. PubMed ID: 22515608
[No Abstract] [Full Text] [Related]
6. Efficacy and pharmacogenomic biomarkers in breast cancer.
Paul AK; Schwab RB
Biomark Med; 2012 Apr; 6(2):211-21. PubMed ID: 22448796
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer as a model of realistic challenges in pharmacogenomics.
Tsongalis GJ; Ricci A
Clin Biochem; 2003 Mar; 36(2):89-94. PubMed ID: 12633756
[No Abstract] [Full Text] [Related]
8. Pharmacogenetics in the treatment of breast cancer.
Stearns V; Davidson NE; Flockhart DA
Pharmacogenomics J; 2004; 4(3):143-53. PubMed ID: 15024382
[No Abstract] [Full Text] [Related]
9. Not quite pharmacogenomics.
Haseltine WA
Nat Biotechnol; 1998 Dec; 16(13):1295. PubMed ID: 9853593
[No Abstract] [Full Text] [Related]
10. Individualized chemotherapy treatment for breast cancer: is it necessary? Is it feasible?
Pusztai L; Rouzier R; Wagner P; Symmans WF
Drug Resist Updat; 2004 Dec; 7(6):325-31. PubMed ID: 15790543
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics of aromatase inhibitors.
Hadfield KD; Newman WG
Pharmacogenomics; 2012 Apr; 13(6):699-707. PubMed ID: 22515612
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomics and breast cancer.
Lymberis SC; Parhar PK; Katsoulakis E; Formenti SC
Pharmacogenomics; 2004 Jan; 5(1):31-55. PubMed ID: 14683419
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacogenomics in chemotherapy and drug development for breast cancer].
Shimizu C; Fujiwara Y
Nihon Rinsho; 2006 Mar; 64(3):424-31. PubMed ID: 16529031
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenomics of third-generation aromatase inhibitors.
Turkistani A; Marsh S
Expert Opin Pharmacother; 2012 Jun; 13(9):1299-307. PubMed ID: 22594760
[TBL] [Abstract][Full Text] [Related]
15. Bladder cancer pharmacogenomics: recent insights and future perspectives.
O'Donnell PH
Pharmacogenomics; 2012 Nov; 13(14):1553-6. PubMed ID: 23148629
[No Abstract] [Full Text] [Related]
16. CYP2D6 pharmacogenomics of tamoxifen treatment.
Technol Eval Cent Assess Program Exec Summ; 2008 May; 23(1):1-4. PubMed ID: 18663817
[No Abstract] [Full Text] [Related]
17. Evaluation and identification of reliable reference genes for pharmacogenomics, toxicogenomics, and small RNA expression analysis.
Chen D; Pan X; Xiao P; Farwell MA; Zhang B
J Cell Physiol; 2011 Oct; 226(10):2469-77. PubMed ID: 21412770
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenomics in breast cancer: current trends and future directions.
Wajapeyee N; Somasundaram K
Curr Opin Mol Ther; 2004 Jun; 6(3):296-301. PubMed ID: 15264432
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics of breast cancer: toward the individualization of therapy.
Chang JC; Hilsenbeck SG; Fuqua SA
Cancer Invest; 2009 Aug; 27(7):699-703. PubMed ID: 19637041
[No Abstract] [Full Text] [Related]
20. Breast cancer biomarkers and molecular medicine: part II.
Ross JS; Linette GP; Stec J; Clark E; Ayers M; Leschly N; Symmans WF; Hortobagyi GN; Pusztai L
Expert Rev Mol Diagn; 2004 Mar; 4(2):169-88. PubMed ID: 14995904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
